Clinical Trial

A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of secukinumab 300mg in Chinese adults participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-03-20.
Trial Details
NCT Number NCT05303285
Lead Sponsor Tongji Hospital
Collaborators: Wuhan Central Hospital, Wuhan Hospital of Traditional Chinese Medicine, Novartis, Johns Hopkins Bloomberg School of Public Health
Conditions Ankylosing Spondylitis (AS)
Enrollment 100 participants
Start Date 2024-06-14
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-27